Enanta Pharmaceuticals, Inc.
ENTA · NASDAQ
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$81,889 | -$116,045 | -$133,816 | -$121,755 |
| Dep. & Amort. | $5,089 | $2,336 | $2,371 | $2,973 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $18,565 | $26,795 | $28,216 | $26,969 |
| Change in WC | -$1,547 | $7,130 | $8,024 | $6,789 |
| Other Non-Cash | $40,510 | $1,020 | -$7,949 | $242 |
| Operating Cash Flow | -$19,272 | -$78,764 | -$103,154 | -$84,782 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$12,896 | -$17,948 | -$9,058 | -$2,125 |
| Net Acquisitions | $0 | $0 | $44,520 | -$54,897 |
| Inv. Purchases | -$209,629 | -$307,282 | -$373,391 | -$171,446 |
| Inv. Sales/Matur. | $262,872 | $383,465 | $328,871 | $228,468 |
| Other Inv. Act. | $0 | $0 | -$44,520 | $54,897 |
| Investing Cash Flow | $40,347 | $58,235 | -$53,578 | $54,897 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | -$27,479 | $0 | $0 |
| Stock Issued | $0 | $0 | $0 | $0 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | -$26,618 | -$147 | $198,126 | $20,033 |
| Financing Cash Flow | -$26,618 | -$27,626 | $198,126 | $20,033 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | -$5,543 | -$48,155 | $41,394 | -$9,852 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $41,201 | $89,356 | $47,962 | $57,814 |
| End Cash | $35,658 | $41,201 | $89,356 | $47,962 |
| Free Cash Flow | -$32,168 | -$96,712 | -$112,212 | -$86,907 |